↓ Skip to main content

A phase 2, open-label study of brentuximab vedotin in patients with CD30-expressing solid tumors

Overview of attention for article published in Investigational New Drugs, April 2019
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
1 X user

Readers on

mendeley
27 Mendeley